Analysts Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) PT at $7.25

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have received an average recommendation of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $6.75.

A number of research analysts have recently issued reports on the stock. JMP Securities restated a “market outperform” rating and issued a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Esperion Therapeutics Stock Performance

Shares of NASDAQ ESPR opened at $1.88 on Thursday. The company has a market capitalization of $370.44 million, a P/E ratio of -2.94 and a beta of 1.01. Esperion Therapeutics has a 52-week low of $1.58 and a 52-week high of $3.94. The company’s 50 day moving average price is $2.28 and its 200-day moving average price is $2.12.

Institutional Trading of Esperion Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Boomfish Wealth Group LLC increased its stake in Esperion Therapeutics by 17.1% during the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 5,102 shares in the last quarter. Summit Financial LLC increased its stake in Esperion Therapeutics by 18.2% during the 4th quarter. Summit Financial LLC now owns 46,528 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 7,150 shares in the last quarter. Foundations Investment Advisors LLC increased its stake in Esperion Therapeutics by 48.6% during the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 9,872 shares in the last quarter. Traphagen Investment Advisors LLC bought a new stake in Esperion Therapeutics during the 3rd quarter valued at $27,000. Finally, Cibc World Markets Corp bought a new stake in Esperion Therapeutics during the 4th quarter valued at $39,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.